Chicago-based Novaerus, developer of airborne pathogen control technology designed for long-term care environments, has received $10 million in funding through investment partnerships with Polaris Partners, a global healthcare technology venture capital firm, and Fidelity Biosciences, Cambridge, Mass., a health/medical subsidiary of Fidelity Investments.
Novaerus’ air sterilization system uses plasma barriers to scrub out bacteria, mold and allergens from the air, a technology that has shown to be effective in controlling Norovirus, influenza and Methicillin-resistant Staphylococcus aureus, along with other pathogens that can spread rapidly through nursing home environments.
"Infection control is a critical issue facing the senior care market," said Jon Lim, principal at Fidelity Biosciences, in a press release announcing the deal. "Novaerus’ breakthrough technology is a unique and compelling solution to reduce airborne pathogens and keep medical costs down in these facilities."
Added Bill McCabe, chairman and chief executive officer of Novaerus: "This investment will allow us to capture greater share in the long-term care market, while also establishing our position in adjacent healthcare markets."